Clobetasol propionate emulsion formulation foam 0.05%: Review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents
- 30 September 2008
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 59 (3), 448-454.e1
- https://doi.org/10.1016/j.jaad.2008.04.020
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A clinician's paradigm in the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Psoriasis—recent advances in understanding its pathogenesis and treatmentJournal of the American Academy of Dermatology, 2005
- Atopic DermatitisNew England Journal of Medicine, 2005
- Validity of composite end points in clinical trialsBMJ, 2005
- Disease management of atopic dermatitis: an updated practice parameterAnnals of Allergy, Asthma & Immunology, 2004
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 2004
- Composite Outcomes in Randomized TrialsJAMA, 2003
- The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp RegionsJournal of Cutaneous Medicine and Surgery, 2003
- PsoriasisThe Lancet, 2003
- Clobetasol propionate foam 0.05%: a novel vehicle with enhanced deliveryInternational Journal of Dermatology, 2000